Acquire InVite Health LactoSpore – a friendly bacterium for your child’s health
  • < FREE SHIPPING with your $50+ order > < FREE SHIPPING with your $50+ order >
Listen to InVite Radio LIVE!
InviteHealth      
InviteHealth      
     

LactoSpore – a friendly bacterium for your child’s health

Gastro-intestinal and associated effects

Clinical trials performed in Japan with LACBON 60 (L. sporogenes*)

Reports from various hospitals that performed clinical trials on groups of patients suffering from a variety of intestinal disorders and allergic skin diseases are summarized in Table 5.1.

It is evident that the administration of L. sporogenes* markedly improved the general clinical condition of the subjects and provided relief from intestinal disorders and allergic skin conditions. Allergic skin conditions can be related to an imbalance of intestinal flora in the subject. This condition was therefore corrected by L. sporogenes* therapy in these trials.

SUMMARY OF SELECTED CLINICAL REPORTS FROM JAPAN: TRIALS WITH LACBONÒ (L. sporogenes*)

  1. Condition: Acute and chronic intestinal catarrh (inflammation of the mucous membranes)

    No. of subjects: 38

    Treatment: 100-600 million spores/ day in divided doses for 2-12 days

    Effectiveness rate: 86.8%

    Conclusion: Recovery from diarrhea to regular normal stools; general symptoms including anorexia improved

  2. Condition: Diarrhea

    No. of subjects: 15

    Treatment: 75-600 million spores/ day in divided doses for 3-12 days

    Effectiveness rate: 100%

    Conclusion: Recovery from diarrhea to regular, normal stools from third to fourth day

  3. Condition: Constipation

    No. of subjects: 10

    Treatment: 300-750 million spores / day in divided doses for 2-10 days

    Effectiveness rate: 70.0%

    Conclusion: Recovery to normal stools and disappearance of abdominal distention

  4. Condition: Abnormal intestinal fermentation

    No. of subjects: 9

    Treatment: 300-600 million spores / day in divided doses for 3-14 days

    Effectiveness rate: 100.0%

    Conclusion: Vomiting and nausea disappeared; appetite improved; stools became normal and regular; diarrhea and stomach ache cured.

  5. Condition: Dyspepsia infantum

    No. of subjects: 26

    Treatment: 100-200 million spores / day in divided doses for 1-7 days

    Effectiveness rate: 84.6%

    Conclusion: General conditions and nature of stools improved. Frequency of stools decreased to half or less than that before medication.

  6. Condition: Allergic skin diseases

    No. of subjects: 5

    Treatment: 200-450 million spores / day in divided doses for 4-12 days

    Effectiveness rate: 80.0%

    Conclusion: Obvious eruptions of strophulus and eczema decreased from the third day (topical therapy employed concomitant

  7. Condition: Miscellaneous symptoms

    No. of subjects: 10

    Treatment: 20-50 million spores / day in divided doses for 4-20 days

    Effectiveness rate: 80.0%

Conclusion: Response seen in anorexia of nervous type and malnutrition in infants

The above data are cited from clinical reports by: Terumichi Kuniya, Pediatric Clinic of Shinko Hospital, Kobe; Jetsuo Nitta, Medical Clinic of Kugason Hospital; Goro Koide, Pediatric Clinic of Kanto Teishin Hospital; Michio Ogasawara, Medical Clinic of Kahoku Hospital; Susumu Nakazawa, Pediatric Clinic of Ebara Hospital.

In a study in Japan a success rate of 78.4% with SPORLAC treatment for infantile diarrhea was obtained. An earlier study in India by Mathur et al. found the average time for improvement in diarrheal conditions to be two to three days, with treatment.

1 | 2 | 3 | 4 | 5